GlassScriptPhysician profile
Deirdre J Cohen
NPI 1275759318
$39,836.57
in general payments reported to CMS, 2019-2025
28 companies · $16K in 2025
The $16K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $2,463 · 2021: $1,725 · 2022: $6,394 · 2023: $3,555 · 2024: $9,649 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Consulting Fee: $7,920 · Travel and Lodging: $2,674 · Honoraria: $2,400 · Food and Beverage: $1,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,962.50 |
| Consulting Fee | $7,920.00 |
| Travel and Lodging | $2,674.38 |
| Honoraria | $2,400.00 |
| Food and Beverage | $1,297.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $21,608.16 | 2021-2025 | Vyloy |
| Incyte Corporation | $4,436.35 | 2025 | Zynyz |
| Fosun Pharma USA INC. | $2,587.29 | 2024 | |
| Seagen INC. | $1,750.00 | 2023 | Tukysa |
| Eli Lilly and Company | $1,664.86 | 2024 | |
| Eisai INC. | $1,634.73 | 2022 | |
| Beigene USA, INC. | $1,625.00 | 2024 | Tevimbra |
| Taiho Oncology, INC. | $1,562.50 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $1,365.66 | 2025 | Imfinzi |
| Bayer Healthcare Pharmaceuticals INC. | $920.74 | 2020-2025 | |
| Foundation Medicine, INC. | $229.00 | 2022 | |
| Biontech Se | $153.17 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $91.50 | 2025 | Onivyde |
| Novartis Pharmaceuticals Corporation | $90.01 | 2023 | |
| Beone Medicines USA, INC. | $72.21 | 2025 | Tevimbra |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $23.77 | 2025 | Xt Cdx |
| Daiichi Sankyo INC. | $21.62 | 2025 | Enhertu |
11 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deirdre Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.